denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: General Sessions
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Biological therapies, Clinical Practice (Health Services and Quality), drug development, Diseases, SARS-CoV-2/COVID-19, thrombotic disorders, Infectious Diseases, Therapies, Vaccines
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Biological therapies, Clinical Practice (Health Services and Quality), drug development, Diseases, SARS-CoV-2/COVID-19, thrombotic disorders, Infectious Diseases, Therapies, Vaccines
Tuesday, December 13, 2022: 11:00 AM-12:30 PM
Hall E
(Ernest N. Morial Convention Center)
Lecture Title:
What the Hematologist Has Learned from the Pandemic
Chair:
Jane N. Winter, MD, Robert H. Lurie Comp. Cancer Center
Disclosures:
Winter: Daiichi Sankyo: Other: for Spouse, to the University of Chicago, Research Funding; Novartis: Consultancy, Other: for Spouse, to the University of Chicago, Research Funding; Rafael: Other: For Spouse, to University of Chicago, Research Funding; Forty Seven/Gilead: Other: For Spouse, to University of Chicago, Research Funding; Astellas: Other: For Spouse, to University of Chicago, Research Funding; CVS/Caremark: Consultancy, Other: For Spouse; Servier: Consultancy, Other: For Spouse; Cellectis: Other: for Spouse, to the University of Chicago, Research Funding; Merck & Co., Inc.: Honoraria, Research Funding.
Now in its third year, the SARS-CoV-2 pandemic persists and continues to evolve. There have been many lessons learned from the standpoint of public health, but also from our efforts to manage the complications of infection and to develop preventative and therapeutic strategies. The hematologist has been called upon to address issues of thrombosis and thrombocytopenia related to COVID-19 but also as complications of vaccination. The application of mRNA technology led to highly effective vaccines within months, a previously unheard of timeline. Yet, our immunocompromised patients have suffered disproportionately from infection and have in many cases failed to benefit from vaccination. Our speakers will address the hematologic impact of SARS-CoV-2 infection and vaccination, the development of the mRNA vaccines and future applications of mRNA technology, and our current understanding of the immune response to SARS-CoV-2 and vaccination.
Dr. Beverly Hunt will speak on thrombosis and coagulopathy in COVID-19 including immune-mediated thrombocytopenia and thrombosis related to vaccination.
Dr. Shane Crotty will discuss the immune response to SARS-CoV-2 and vaccination including implications for the care of immunocompromised patients.
Dr. Drew Weissman will speak on the development of the COVID-19 mRNA vaccines and emerging applications of mRNA technology.
See more of: General Sessions